Calano Sarah J, Shih Pei-An B, Liu Chau-Ching, Kao Amy H, Navratil Jeannine S, Manzi Susan, Ahearn Joseph M
Lupus Center of Excellence, University of Pittsburgh School of Medicine, USA.
Adv Exp Med Biol. 2006;586:381-90. doi: 10.1007/0-387-34134-X_25.
Measurement of serum C3 and C4 has been used for several decades to monitor disease activity in patients with SLE. Despite the limited utility and recognized weaknesses of these assays, they have remained the gold standard during an era of unprecedented discovery in the complement field. The current urgent need for lupus biomarkers warrants efforts to mine the complement system for assays superior to serum C3 and C4. Recent studies of soluble and cell-bound complement activation products hold promise for achieving this goal.
几十年来，血清C3和C4的检测一直被用于监测系统性红斑狼疮（SLE）患者的疾病活动情况。尽管这些检测方法的实用性有限且存在公认的缺点，但在补体领域取得前所未有的发现的时代，它们仍然是金标准。当前对狼疮生物标志物的迫切需求促使人们努力在补体系统中挖掘比血清C3和C4更优的检测方法。最近对可溶性和细胞结合补体激活产物的研究有望实现这一目标。
